| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_26b2ef5cf79757438bb5e2bb1dce0946
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18d92c46f60af8af24e262b67381d7eb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001139
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-208
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-193
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 |
| filingDate |
2013-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38080402ed4382df39be17fadee9350e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a15fbd41b68a39ff6d199eeded64eff0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2815044743c471adbf4b77ffb80a8dfd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad5a5745013d00cfdba33c2c64443ff3 |
| publicationDate |
2015-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2858722-A1 |
| titleOfInvention |
Compostions and methods for cancer immunotherapy |
| abstract |
The present invention provides a combination therapy which relies on a small molecule immune stimulator - cyclic-di-nucleotide (CDN) - that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes) formulated with allogeneic human tumor cell lines engineered to secrete high amounts of GM-CSF. This combination therapy can provide an ideal synergy of multiple tumor associated antigens, DC recruitment and proliferation, coupled with a potent DC activation stimulus. |
| priorityDate |
2012-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |